Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
GHRS
GHRS
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
GHRS News
Rapid Growth in Major Depressive Disorder Treatment Market
Jun 30 2026
Newsfilter
Helus Pharma's HLP003 Phase 3 Trial Enrollment Surpasses 86%
Jun 26 2026
PRnewswire
Helus Pharma's HLP003 Phase 3 Trial Surpasses 86% Enrollment
Jun 26 2026
Newsfilter
GH Research Announces Phase 2a Results for GH001 in Treating Post-Partum Depression
Jun 05 2026
NASDAQ.COM
GH Research Reports Strong Cash Position Amid Q1 Loss
May 14 2026
seekingalpha
GH Research Prices $117.5 Million Stock Offering
Apr 29 2026
seekingalpha
Trump Signs Executive Order to Accelerate Psychedelic Research
Apr 20 2026
CNBC
Trump Signs Executive Order on Psychedelics, Boosting Compass Pathways Stock
Apr 20 2026
Yahoo Finance
Trump Signs Executive Order to Accelerate Psychedelic Drug Reviews
Apr 20 2026
Newsfilter
Trump Administration to Examine Safety of Psychedelic Drug for PTSD
Apr 18 2026
Yahoo Finance
Trump Administration to Examine Ibogaine Research for PTSD Funding
Apr 16 2026
stocktwits
GH001 Shows Promising Results in Treatment-Resistant Depression Study
Mar 25 2026
Newsfilter
Helus Pharma Advances New Drug for Anxiety Treatment
Mar 09 2026
Newsfilter
Helus Pharma Advances Mental Health Treatments with Promising Phase 2 Results
Mar 09 2026
PRnewswire
GH Research Reports FY 2025 Financial Results
Mar 05 2026
seekingalpha
Helus Pharma Advances Mental Health Drug Development
Feb 27 2026
Newsfilter
Show More News
